Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine Patch in Alzheimer's Disease Switched From Oral ChE Inhibitors
NCT01529619Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2012
- Primary completion
- Dec 2013
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of rivastigmine in Alzheimer's disease (AD), sponsored by Novartis. Started Mar 2012; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01529619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01529619.